Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK Biologicals' investigational vaccine GSK2590066A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | Subjects will receive 2 doses of a formulation of GSK2590066A vaccine at a 21-day interval. |
| Group B | EXPERIMENTAL | Subjects will receive 2 doses of a formulation of GSK2592984A vaccine at a 21-day interval. |
| Group C | PLACEBO_COMPARATOR | Subjects will receive 2 doses of a placebo at a 21-day interval. |
| Group D | EXPERIMENTAL | Subjects will receive 2 doses of a formulation of GSK2590066A vaccine at a 21-day interval. |
| Group E | EXPERIMENTAL | Subjects will receive 2 doses of a formulation of GSK2340274A vaccine at a 21-day interval. |
| Group F | EXPERIMENTAL | Subjects will receive 2 doses of a formulation of GSK2340273A vaccine at a 21-day interval. |
| Name | Type | Description |
|---|---|---|
| GSK Biologicals' investigational vaccine GSK2590066A | BIOLOGICAL | Intramuscular injection, two doses |
| GSK Biologicals' investigational vaccine GSK2592984A | BIOLOGICAL | Intramuscular injection, two doses |
| GSK Biologicals' investigational vaccine GSK2340274A | BIOLOGICAL | Intramuscular injection, two doses |
| GSK Biologicals' investigational vaccine GSK2340273A | BIOLOGICAL | Intramuscular injection, two doses |
| Placebo | OTHER | Intramuscular injection, two doses |
Inclusion Criteria: * Subjects who the investigator believes can and will comply with the requirements of the protocol. * Written informed consent obtained from the subject. * Male and female adults, 18-49 years of age at the time of the first vaccination. * Satisfactory baseline medical assessment...